Pharvaris (NASDAQ:PHVS) Hits New 12-Month Low – Should You Sell?

Pharvaris (NASDAQ:PHVS) hit a new 52-week low on Wednesday . The company traded as low as $15.00 and last traded at $15.60, with a volume of 35777 shares trading hands. The stock had previously closed at $15.54.

Analyst Ratings Changes

Separately, JMP Securities lifted their price objective on Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, January 31st.

Pharvaris Stock Performance

The business has a fifty day moving average price of $17.99 and a 200 day moving average price of $19.34. The firm has a market capitalization of $808.40 million, a price-to-earnings ratio of -5.52 and a beta of -3.07.

Institutional Trading of Pharvaris

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc raised its holdings in shares of Pharvaris by 11.2% during the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company’s stock valued at $189,000 after buying an additional 994 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Pharvaris by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company’s stock worth $735,000 after purchasing an additional 1,356 shares during the last quarter. Deutsche Bank AG lifted its holdings in Pharvaris by 13.0% in the 4th quarter. Deutsche Bank AG now owns 18,168 shares of the company’s stock worth $348,000 after purchasing an additional 2,087 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock valued at $59,000 after purchasing an additional 2,847 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Pharvaris in the third quarter valued at $57,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.